Compared with placebo , evolocumab at both dosing schedules led to a significant reduction in mean LDL cholesterol at week @ ( every-@-weeks dose : @ % reduction -LSB- @ % CI @-@ -RSB- , monthly dose : @ % reduction -LSB- @-@ -RSB- ; both p < @ ) and at the mean of weeks @ and @ ( @ % reduction -LSB- @ % CI @-@ -RSB- and @ % reduction -LSB- @-@ -RSB- ; both p < @ ) .